Foresite et al. in $41.5m series-A for Bit Bio
Foresite Capital, Blueyard Capital and Arch Venture Partners have participated in a $41.5m series-A for cell coding company Bit Bio.
The round was led by Richard Klausner, the former director of the National Cancer Institute and founder of Lyell Immunopharma.
Foresite is currently investing from its fourth-generation fund, which closed on $668m in 2018.
Existing backer Blueyard is a Germany-based venture capital investor.
US-based Arch Venture Partners provides investments from $50,000-150m.
The injection of funding is intended to enable Bit Bio to hire more staff and expand its operations.
Previous funding
Business angels Weslie Janeway, Nikolaus Starzacher, Jonathan Milner and Darrin Disley contributed £350,000 in 2017.
Blueyard also provided an undisclosed seed investment in 2019.
Company
Cambridge-based Bit Bio is a synthetic biology company focused on combining data science and biology to code cells. Coding can allow the reprogramming of stem cells to induce them to become liver, brain or immune system cells. The company was founded in 2016 as a spin-out from Cambridge University.
People
Bit Bio – Mark Kotter (founder, CEO).
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater